Coloplast (COLO-B) Stock Price, Fundamentals & Analysis

What COLO-B does

Coloplast (COLO-B) is a Healthcare stock listed on the Nasdaq Copenhagen under the symbol COLO-B. Headquartered in Humlebæk, Denmark, the company develops and sells intimate healthcare products and services across Denmark, the United States, the United Kingdom, France, and internationally. Coloplast operates through several segments, including Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics. Its product portfolio includes ostomy care solutions such as SenSura Mio and Brava accessories, continence care products like Conveen Active urine bags and SpeediCath catheters, and wound care offerings under the Biatain Silicone and Comfeel brands. With 17,213 employees, Coloplast competes in the Medical Instruments & Supplies industry alongside peers such as GN Store Nord (GN), Zealand Pharma (ZEAL), Genmab (GMAB), and Demant (DEMANT).

Key numbers explained

• Price: 417.6 DKK — the current trading price of one share on the Nasdaq Copenhagen.
• Market cap: 94.11 mld. DKK — the total market value of all outstanding shares, calculated as share price multiplied by the number of shares.
• Trailing P/E ratio: 34 — the share price divided by trailing 12‑month earnings per share (12.28 DKK), indicating how much investors pay per unit of recent earnings.
• Forward P/E ratio: 16 — the share price relative to expected future earnings, often viewed as a more forward‑looking valuation measure.
• Dividend yield: 5.51% — the annual dividend per share expressed as a percentage of the current price, reflecting the cash return to shareholders.
• Ex‑dividend date: May 18, 2026 — the date on or after which a buyer is no longer entitled to the next dividend payment.
• Share of earnings paid out as dividends: 188% — the dividend payout ratio, showing that Coloplast distributes more than its reported earnings as dividends.
• Beta: 0.56 — a measure of the stock’s volatility relative to the broader market, with values below 1 suggesting lower sensitivity to market swings.
• Price change over the last 52 weeks: -23.7% — the percentage change from the price one year ago to the current price.
• Revenue, trailing 12 months: 28.44 mld. DKK — total sales over the past 12 months, with a year‑over‑year growth of 5.7%.
• Profit margin: 9.7% — the percentage of revenue that remains as profit after all expenses.
• Operating margin: 26.2% — the percentage of revenue left after covering operating costs, before interest and taxes.
• Return on equity: 18.5% — a measure of how effectively the company generates profit from shareholders’ equity.
• Debt‑to‑equity ratio: 178.1% — total debt divided by shareholders’ equity, indicating the degree to which the company is financed by debt.
• Price‑to‑book: 7.03 — the market price per share relative to the book value per share.
• Next earnings date: Nov 3, 2026 — the scheduled date for the company’s next earnings release.

What to watch

Investors tracking COLO-B may consider factors common to the Healthcare sector and Medical Instruments & Supplies industry. Revenue growth, margins, and product innovation in areas such as ostomy and continence care can influence long‑term performance. The dividend policy and payout ratio are relevant for income‑focused investors, while the debt‑to‑equity level may affect financial flexibility. As a component of the OMXC25, COLO-B’s movements can be influenced by broader Danish and European market trends. For those building a diversified portfolio, comparing COLO-B with other Danish healthcare names such as Ambu (AMBU-B) or international peers like Takeda Pharmaceutical (4502) can provide context.